PHASE-I TRIAL OF PALA
- 1 January 1980
- journal article
- research article
- Vol. 64 (12) , 1301-1305
Abstract
PALA [N-(phosphonacetyl)-L-aspartate] was given i.v. on a weekly schedule to 32 patients with advanced malignant tumors. A course of treatment consisted of 3 weekly doses. Patients were treated at 8 dose levels, ranging from 900-6750 mg/m2. Gastrointestinal toxicity (diarrhea) and skin rash were dose-limiting. No consistent myelosuppression occurred; no renal or hepatic toxicity was observed. Two patients who did not have metastatic intracranial disease experienced episodes of encephalopathy and seizures. No major therapeutic responses were observed during this phase I trial; minor responses (.gtoreq. 25% tumor decrease) occurred in 3 patients (1 with adenocarcinoma of the lung and 2 with epidermoid carcinoma of the bladder). Doses of 4500 mg/m2 per wk for patients with a performance status .gtoreq. 70 and 3750 mg/m2 per wk for patients with a lower performance status are recommended for phase II studies.This publication has 6 references indexed in Scilit:
- MECHANISMS OF SENSITIVITY OR RESISTANCE OF MURINE TUMORS TO N-(PHOSPHONACETYL)-L-ASPARTATE (PALA)1979
- EFFECTS OF N-(PHOSPHONACETYL)-L-ASPARTATE ON MURINE TUMORS AND NORMAL TISSUES INVIVO AND INVITRO AND RELATIONSHIP OF SENSITIVITY TO RATE OF PROLIFERATION AND LEVEL OF ASPARTATE-TRANSCARBAMYLASE1978
- SELECTIVE-INHIBITION OF PYRIMIDINE BIOSYNTHESIS AND EFFECT ON PROLIFERATIVE GROWTH OF COLONIC CANCER-CELLS1977
- Reversal of toxicity and antitumor activity of N-(phosphonacetyl)-L-aspartate by uridine or carbamyl-DL-aspartate in vivoBiochemical Pharmacology, 1977
- ANTITUMOR ACTIVITY OF N-(PHOSPHONACETYL)-L-ASPARTIC ACID, A TRANSITION-STATE INHIBITOR OF ASPARTATE-TRANSCARBAMYLASE1976
- Comparative Activties of Aspartate Transcarbamylase in Various Tissues of the Rat.Experimental Biology and Medicine, 1967